(查看文章请点击文末阅读原文)
基于上述局限性,临床中急需一种新颖而准确的检测方法来弥补乳腺钼靶在早期乳腺癌检测中的不足。
庞达教授团队表示,随着近年来高通量测序技术的普及,血浆游离核酸检测获得了突飞猛进的发展,在肿瘤诊断和治疗方面发挥越来越重要的作用。本次研究表明血浆游离核酸甲基化检测在乳腺癌诊断方面表现优越,有挑战传统影像学的趋势,有望弥补乳腺钼靶检查的不足。
以下为本研究的内容分享
图1:乳腺癌游离DNA甲基化研究流程图
图2:甲基化模型与钼靶对乳腺癌诊断能力比较
[1] Sung H, Ferlay J, Siegel RL, Laversanne M,Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCANestimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA: a cancer journal for clinicians. 2021;71(3):209-49.
[2] Hackshaw A. The benefitsand harms of mammographic screening for breast cancer: building the evidencebase using service screening programmes. SAGE Publications Sage UK: London,England; 2012.
[3] Ohuchi N, Suzuki A,Sobue T, Kawai M, Yamamoto S, Zheng Y-F, et al. Sensitivity and specificity ofmammography and adjunctive ultrasonography to screen for breast cancer in theJapan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlledtrial. The Lancet. 2016;387(10016):341-8.
引领精准医疗,造福千家万户